Literature DB >> 32119177

Long noncoding RNA LINC00630 promotes radio-resistance by regulating BEX1 gene methylation in colorectal cancer cells.

Feng Liu1, Weifeng Huang2, Jinsheng Hong1, Chuanshu Cai1, Weijian Zhang1, Jianrong Zhang3, Zhenming Kang4.   

Abstract

This study aimed to analyze the relation between long noncoding RNA (lncRNA) LINCE00630 and radio-resistance and elucidate the underlying mechanism. Relative expression of LINC00630, BEX1, and DNMT3B in colorectal cancer (CRC) cells and clinical samples was determined by real-time PCR. Prognosis in respect of LINC00630 expression was analyzed by Kaplan-Meier survival curve. LINC00630 and BEX1 were specifically silenced by shRNAs. Cell viability and growth were analyzed by MTT and clonogenic assays, respectively. Cell apoptosis was measure by both caspase-3 activity and flow cytometry. Association between EZH2 with LINC00630 and BEX1 promoter was determined by RNA immunoprecipitation and chromatin immunoprecipitation. BEX1 and DNMT3B proteins were quantified by Western blot. We demonstrated the elevated LINC00630 correlated with radio-resistance and poorer prognosis in CRC. Knockdown of LINC00630 significantly improved the sensitivity of CRC cells to irradiation. Mechanistically, LINC00630 in complex with EZH2 negatively regulated BEX1 through promoter DNA methylation. BEX1 silencing greatly restored the cell viability and suppressed cell apoptosis, which were elicited by LINC00630 deficiency in response to irradiation. Our data uncovered the contribution of elevated LINC00630 to radio-resistance in CRC, which was predominately mediated by epigenetically repressed BEX1.
© 2020 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  BEX1; EZH2; LINC00630; colorectal cancer; methylation

Year:  2020        PMID: 32119177     DOI: 10.1002/iub.2263

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  7 in total

Review 1.  Potentials of long non-coding RNAs as biomarkers of colorectal cancer.

Authors:  Yan Lv; Yanhua Wang; Zhikai Zhang; Jiarui Bao; Huahua Su
Journal:  Clin Transl Oncol       Date:  2022-05-17       Impact factor: 3.340

Review 2.  Recent advances in targeted drug delivery systems for resistant colorectal cancer.

Authors:  Masoumeh Sharifi-Azad; Marziyeh Fathi; William C Cho; Abolfazl Barzegari; Hamed Dadashi; Mehdi Dadashpour; Rana Jahanban-Esfahlan
Journal:  Cancer Cell Int       Date:  2022-05-19       Impact factor: 6.429

3.  LncRNAs as Theragnostic Biomarkers for Predicting Radioresistance in Cancer: A Systematic Review and Meta-Analysis.

Authors:  Ping Lin; Wenmin Xing; Qian Ren; Qin Wang; Jing Yan; Genxiang Mao
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia.

Authors:  Zhang Chen; Fan Yang; Hui Liu; Fan Fan; Yanggang Lin; Jinhua Zhou; Yun Cai; Xiaoxiao Zhang; Yingxin Wu; Rui Mao; Tongtong Zhang
Journal:  Aging (Albany NY)       Date:  2021-06-09       Impact factor: 5.682

Review 5.  LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond.

Authors:  Wanxu Huang; Hua Li; Qingsong Yu; Wei Xiao; Dan Ohtan Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-03-15

6.  LINC00630 promotes cholangiocarcinoma cell proliferation, migration and invasion by mediating the miR-199a/FGF7 axis.

Authors:  Baiyin Zhong; Caixin Song; Qingfang He; Zhixi Chen; Qicheng Liao; Qiusheng Xiong; Shijie Wang; Yuansheng Xiao; Xing Xie; Yuankang Xie; Xiaonong Wang; Jianhong Zhang
Journal:  J Cancer       Date:  2022-01-04       Impact factor: 4.207

Review 7.  Role of non-coding RNAs in radiosensitivity of colorectal cancer: A narrative review.

Authors:  Chun-Ming Huang; Hsiang-Lin Tsai; Yen-Cheng Chen; Ching-Wen Huang; Ching-Chun Li; Wei-Chih Su; Tsung-Kun Chang; Yung-Sung Yeh; Po-Jung Chen; Ming-Yii Huang; Jaw-Yuan Wang
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.